Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livoletide in Prader-Willi Syndrome
NCT03790865Phase 3Terminated
- Sponsor
- Millendo Therapeutics
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 8
01
Overview
A Phase 3 trial of livoletide in Prader-Willi syndrome (PWS), sponsored by Millendo Therapeutics. Started Mar 2019; status: terminated.
02
Drugs
livoletide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT03790865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790865.